Lupin Limited has opened its new Center of Excellence for Inhalation Research in Coral Springs, Florida. Lupin’s new facility will focus on the research and development of inhalation products for the treatment of asthma, allergic rhinitis, chronic obstructive pulmonary diseases,and other lung diseases. ”

Lupin has made other recent moves to build its position in the US market. To build its position in the US generics market, in July 2015, Lupin agreed to acquire GAVIS Pharmaceuticals LLC and Novel Laboratories Inc. (GAVIS) for $880 million. GAVIS, based in Somerset, New Jersey, is a privately held company specializing in formulation development, manufacturing, packaging, sales, marketing, and distribution of pharmaceuticals products. The acquisition enhances Lupin’s scale in the US generics market and also broadens Lupin’s pipeline in dermatology, controlled substance products, and niche generics and will provide Lupin with its first manufacturing facility in the United States. GAVIS’ facilities includes 45,000 square feet of R&D and manufacturing space with an additional 105,000 square feet of newly constructed space coming on line by the end of 2015, complemented by 124,000 square feet of packaging and distribution operations. That deal is subject to certain closing conditions and has been unanimously approved by the boards of directors of Lupin and GAVIS.

Source: Lupin